Status:
COMPLETED
A Registry of Treatment Adherence for Patients With Schizophrenia
Lead Sponsor:
Janssen-Cilag, S.A.
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first genera...
Detailed Description
Recent studies have suggested the superior effectiveness of second generation (atypical) antipsychotic medications over first generation (conventional) antipsychotics in preventing relapse during the ...
Eligibility Criteria
Inclusion
- Patients starting treatment with a new antipsychotic medication, in accordance with product labeling in the local country
- Permitted by their physician and by the patient to participate in a clinical trial
Exclusion
- Patients not meeting all of the inclusion criteria for entry into the study
Key Trial Info
Start Date :
September 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
2046 Patients enrolled
Trial Details
Trial ID
NCT00283517
Start Date
September 1 2003
End Date
May 1 2006
Last Update
April 27 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.